IC
MDGL icon

Ikarian Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Ikarian Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-114,900
Closed -$13.6M – 249
2020
Q3 		$13.6M Buy
114,900
+30,200
+36% +$3.28M 0.99% 24
2020
Q2 		$9.59M Buy
+84,700
New +$8.33M 0.76% 41

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ikarian Capital's MDGL Position: Q3 2023 in Review

Ikarian Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2023, closing a stake of 75 shares — an estimated $17.3K sold.

Ikarian Capital first reported a position in MDGL in Q4 2019 and held it in 12 quarters. The position peaked at $4.82M in Q2 2020. 205 funds tracked by Wall St. Rank hold MDGL as of Q3 2023.

  • Ikarian Capital reported no remaining Madrigal Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Ikarian Capital sold 75 Madrigal Pharmaceuticals shares in Q3 2023, an estimated $17.3K.
  • Ikarian Capital first reported a position in Madrigal Pharmaceuticals in Q4 2019 and held it in 12 quarters.
  • Ikarian Capital's Madrigal Pharmaceuticals position peaked at $4.82M in Q2 2020.
  • 205 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.